MedTrace Logo

Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer

NCT03907800 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-10-27

No results posted yet for this study

Summary

To evaluate the efficacy and safety of nab-paclitaxel combined with carboplatin for Chinese patients with triple-negative and HER2-positive breast cancer in the neoadjuvant setting.

Conditions

Interventions

DRUG

Nab-paclitaxel

125 mg/m² weekly, infusion, 3 weeks on 1 week off, applicated for four cycles.

DRUG

Carboplatin

AUC 2, weekly, 3 weeks on 1 week off, applicated for 4 cycles

DRUG

Herceptin

In case of HER2-positive, patients receive Herceptin weekly during all cycles.

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Li Zhu, Prof. · Ruijin Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2022-10-31
Completion
2022-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03907800 on ClinicalTrials.gov